Extracellular matrix metalloprotease inducer (EMMPRIN or CD147) is a tumor cell surface molecule that is known to promote tumor growth in epithelial malignancies and is highly expressed in head and neck squamous cell carcinoma (HNSCC). We hypothesize that CD147 can be exploited as a therapeutic target in head and neck cancer. We propose to assess the potential of anti-CD147 antibody therapy alone and in combination with concurrent radiation and cisplatin treatment. Furthermore, we propose to determine the role of CD147 in promoting regional metastasis. Although CD147 is known to stimulate fibroblasts to produce matrix metalloproteases (MMPs) and vascular endothelial growth factor (VEGF), we have identified upregulation and secretion of interleukin-12 (IL- 12) in CD147 stimulated fibroblasts. We propose to determine if CD147 promotes the malignant phenotype in vitro and in vivo tumor through modulation of IL-12.

Public Health Relevance

Survival rates for head and neck cancer (HNSCC) have not significantly improved over the past 30 years despite more aggressive treatment and advances in medical treatment. Development of targeted agents against molecules that promote tumor growth have the potential to improve patient outcomes when combined with conventional cytotoxic therapies. We propose to determine if extracellular matrix metalloprotease inducer (EMMPRIN or CD147) is a potential molecular target in HNSCC. The application also seeks to identify the role of CD147 in tumor growth and metastasis using murine orthotopic models of head and neck cancer. Furthermore, novel molecular mechanisms by which CD147 acts to promote the malignant phenotype in vitro and in vivo will be investigated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA142637-04
Application #
8444266
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Yovandich, Jason L
Project Start
2010-04-01
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
4
Fiscal Year
2013
Total Cost
$249,459
Indirect Cost
$79,180
Name
University of Alabama Birmingham
Department
Surgery
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Sorace, Anna G; Korb, Melissa; Warram, Jason M et al. (2014) Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer. Ultrasound Med Biol 40:755-64
Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94
Frederick, John W; Sweeny, Larissa; Carroll, William R et al. (2013) Microvascular anastomotic coupler assessment in head and neck reconstruction. Otolaryngol Head Neck Surg 149:67-70
Kejner, Alexandra E; Burch, M Benjamin; Sweeny, Larissa et al. (2013) Bone morphogenetic protein 6 expression in oral cavity squamous cell cancer is associated with bone invasion. Laryngoscope 123:3061-5
Heath, C Hope; Deep, Nicholas L; Nabell, Lisle et al. (2013) Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85:1275-81
Frederick, John W; Sweeny, Larissa; Carroll, William R et al. (2013) Outcomes in head and neck reconstruction by surgical site and donor site. Laryngoscope 123:1612-7
Magnuson, J Scott; Durst, Jennifer; Rosenthal, Eben L et al. (2013) Increased likelihood of long-term gastrostomy tube dependence in head and neck cancer survivors without partners. Head Neck 35:420-5
Sweeny, Larissa; Hartman, Yolanda E; Zinn, Kurt R et al. (2013) A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma. Oral Oncol 49:991-7
Sweeny, Larissa; Dean, Nichole R; Magnuson, J Scott et al. (2012) EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 34:681-6
Sweeny, Larissa; Liu, Zhiyong; Lancaster, William et al. (2012) Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor. Laryngoscope 122:1539-44

Showing the most recent 10 out of 22 publications